Compare KGS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | PTGX |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.4B |
| IPO Year | 2023 | 2016 |
| Metric | KGS | PTGX |
|---|---|---|
| Price | $76.01 | $121.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $57.17 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.6M | 705.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.20 | 0.05 |
| Revenue | ★ $1,308,100,000.00 | N/A |
| Revenue This Year | $12.30 | $874.25 |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ $370.00 | $2,455.60 |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $30.06 | $49.86 |
| 52 Week High | $77.68 | $126.25 |
| Indicator | KGS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 66.64 |
| Support Level | $65.10 | $94.48 |
| Resistance Level | $77.18 | N/A |
| Average True Range (ATR) | 2.58 | 4.67 |
| MACD | 0.70 | 1.54 |
| Stochastic Oscillator | 99.42 | 77.87 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.